TY - JOUR
T1 - The protective role of small heat shock proteins in cardiac diseases
T2 - key role in atrial fibrillation
AU - Hu, Xu
AU - Van Marion, Denise M.S.
AU - Wiersma, Marit
AU - Zhang, Deli
AU - Brundel, Bianca J.J.M.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Atrial fibrillation (AF) is the most common tachyarrhythmia which is associated with increased morbidity and mortality. AF usually progresses from a self-terminating paroxysmal to persistent disease. It has been recognized that AF progression is driven by structural remodeling of cardiomyocytes, which results in electrical and contractile dysfunction of the atria. We recently showed that structural remodeling is rooted in derailment of proteostasis, i.e., homeostasis of protein production, function, and degradation. Since heat shock proteins (HSPs) play an important role in maintaining a healthy proteostasis, the role of HSPs was investigated in AF. It was found that especially small heat shock protein (HSPB) levels get exhausted in atrial tissue of patients with persistent AF and that genetic or pharmacological induction of HSPB protects against cardiomyocyte remodeling in experimental models for AF. In this review, we provide an overview of HSPBs as a potential therapeutic target for normalizing proteostasis and suppressing the substrates for AF progression in experimental and clinical AF and discuss HSP activators as a promising therapy to prevent AF onset and progression.
AB - Atrial fibrillation (AF) is the most common tachyarrhythmia which is associated with increased morbidity and mortality. AF usually progresses from a self-terminating paroxysmal to persistent disease. It has been recognized that AF progression is driven by structural remodeling of cardiomyocytes, which results in electrical and contractile dysfunction of the atria. We recently showed that structural remodeling is rooted in derailment of proteostasis, i.e., homeostasis of protein production, function, and degradation. Since heat shock proteins (HSPs) play an important role in maintaining a healthy proteostasis, the role of HSPs was investigated in AF. It was found that especially small heat shock protein (HSPB) levels get exhausted in atrial tissue of patients with persistent AF and that genetic or pharmacological induction of HSPB protects against cardiomyocyte remodeling in experimental models for AF. In this review, we provide an overview of HSPBs as a potential therapeutic target for normalizing proteostasis and suppressing the substrates for AF progression in experimental and clinical AF and discuss HSP activators as a promising therapy to prevent AF onset and progression.
KW - Atrial fibrillation
KW - Heat shock protein
KW - Proteostasis
KW - Small HSP (HSPB)
UR - http://www.scopus.com/inward/record.url?scp=85019024373&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s12192-017-0799-4
DO - https://doi.org/10.1007/s12192-017-0799-4
M3 - Article
C2 - 28484965
SN - 1355-8145
VL - 22
SP - 665
EP - 674
JO - Cell Stress and Chaperones
JF - Cell Stress and Chaperones
IS - 4
ER -